Compare Manchester United PLC (MANU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs BIO-TECHNE Corp — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.51B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.2× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and BIO-TECHNE Corp for 63 Days on average.
| MANU | TECH | |
|---|---|---|
Market Cap | $3.51B | $11.36B |
Volume | 412,769 | 5,390,331 |
Sector | Media | Health |
52-Week High | $24.19 | $72.61 |
52-Week Low | $15.20 | $43.31 |
Typical Hold Time | 109 Days | 63 Days |
Enterprise Value | $4.33B | $11.39B |
Dividend Yield | 1.26% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.25, down 0.74% on the day, with a bearish technical signal from moving averages. The company reported fiscal 2026 revenue of $678 million but continues to post net losses, with a -6.34% net income margin. Analyst consensus shows 40% buy ratings versus 60% hold, reflecting cautious optimism about the club's operational recovery and Champions League return despite persistent profitability challenges.
The stock presents a valuation opportunity with a market cap discount to Forbes' $7.2 billion franchise estimate, but faces significant execution risks including sustained losses, high debt levels, and competitive Premier League dynamics. Upside depends on cost management and revenue growth from European competition, while downside risks include continued negative cash flow and league-wide financial pressures.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
